

Re: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer: WOO 2
MESI-STRAT WOO 2 Trial/ MESI-STRAT
EudraCT No. 2020-003960-22

Justification for non-reported secondary endpoints

1. Effect of Anastrozole on peripheral blood mononuclear cells (PBMC)

A batched analysis of the samples within all trials and projects under the MESI-STRAT umbrella has not yet taken place. Anastrozole data have not been analysed within the MESI-STRAT research consortium. Analysis is still pending, as data are still being processed for further downstream analyses.

2. Clinical response of the breast tumor to therapy as assessed by histopathology at EOS

The analysis of this endpoint is dependent on results from the consortium that have not yet been delivered. This endpoint will be analysed in correlation with the aforementioned analyses that have not yet been conducted.

3. Response of the breast tumor as evaluated by ultrasound assessment before surgery and after 3 weeks of treatment with Anastrozole

The analysis of this endpoint is dependent on results from the consortium that have not yet been delivered. This endpoint will be analysed in correlation with the aforementioned analyses that have not yet been conducted.